Despite Concern, Americans Aren't Protecting Themselves Against Diabetes
- Details
- Category: Abbott
Diabetes affects more than 23 million people in the United States today and another 54 million people have pre-diabetes, according to the Centers for Disease Control and Prevention (CDC).
Roche Group sustained its strong sales growth in the first three months of 2010
- Details
- Category: Roche
Group sales grew 9% in local currencies (6% in Swiss francs; 15% in US dollars) to 12.2 billion Swiss francs. The Pharmaceuticals Division's sales increased 10% in local currencies (6% in Swiss francs; 15% in US dollars) to 9.7 billion Swiss francs, maintaining its above-market growth.
Novo Nordisk's operating profit increased by 15% in the first quarter of 2010
- Details
- Category: Novo Nordisk
Reported operating profit increased by 15% to DKK 4,382 million. Adjusted for the impact from currencies, operating profit in local currencies increased by around 20%.
Novartis healthcare portfolio generates strong growth in first quarter of 2010
- Details
- Category: Novartis
Novartis delivered a strong performance in the first quarter of 2010 - particularly the rapid expansion of recently launched products and important regulatory approvals achieved for new medicines and vaccines - as the Group made progress with a sharp focus on innovation, growth and productivity.
World Bank and Pfizer Announce Initiative to Help Improve Healthcare Delivery
- Details
- Category: Pfizer
The World Bank and Pfizer Inc. announced they will collaborate to improve the healthcare infrastructure, specifically the supply chain, in developing countries, starting with Africa.
Superior efficacy of Victoza® (liraglutide) compared to Januvia® (sitagliptin)
- Details
- Category: Novo Nordisk
The Lancet published online the results of the first study comparing the once-daily human GLP-1 analogue, Victoza® (liraglutide) with a DPP-4 inhibitor, Januvia®. The 26-week trial showed that Victoza® produced significantly greater reductions in HbA1c, fasting plasma glucose (FPG) and body weight than Januvia®, with similar or better overall treatment satisfaction.[1]
Pfizer Discontinues Phase 3 Trial of Sutent® in Advanced Hepatocellular Carcinoma
- Details
- Category: Pfizer
Pfizer Inc. announced the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma (HCC), or liver cancer.
More Pharma News ...
- Amgen's First Quarter 2010 Revenue Increased 9 Percent to $3.6 Billion
- Abbott Reports Strong First Quarter Results
- Sandoz to acquire Oriel Therapeutics, gaining rights to portfolio of respiratory products
- Bayer HealthCare Marks 2010 World Hemophilia Day with EUR 250,000 Contribution
- Novo Nordisk launches international survey into the psychosocial effects of living with haemophilia
- Long-term efficacy and tolerability of Vimpat® (lacosamide)
- Stemgent and Pfizer Announce Collaboration